Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation

Masahiko Sumi; Mari Kitahara; Tsutomu Shishido; Hiroko Kazumoto; Nozomu Uematsu; Takehiko Kirihara; Keijiro Sato; Toshimitsu Ueki; Yuki Hiroshima; Hikaru Kobayashi

doi:10.2169/internalmedicine.4863-20

CASE REPORTS

Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation

Masahiko Sumi, Mari Kitahara, Tsutomu Shishido, Hiroko Kazumoto, Nozomu Uematsu, Takehiko Kirihara, Keijiro Sato, Toshimitsu Ueki, Yuki Hiroshima, Hikaru Kobayashi

Author information

Masahiko Sumi
Department of Hematology, Nagano Red Cross Hospital, Japan
Mari Kitahara
Department of Hematology, Nagano Red Cross Hospital, Japan
Tsutomu Shishido
Department of Hematology, Nagano Red Cross Hospital, Japan
Hiroko Kazumoto
Department of Hematology, Nagano Red Cross Hospital, Japan
Nozomu Uematsu
Department of Hematology, Nagano Red Cross Hospital, Japan
Takehiko Kirihara
Department of Hematology, Nagano Red Cross Hospital, Japan
Keijiro Sato
Department of Hematology, Nagano Red Cross Hospital, Japan
Toshimitsu Ueki
Department of Hematology, Nagano Red Cross Hospital, Japan
Yuki Hiroshima
Department of Hematology, Nagano Red Cross Hospital, Japan
Hikaru Kobayashi
Department of Hematology, Nagano Red Cross Hospital, Japan

Keywords: primary myelofibrosis, allogeneic stem cell transplantation, relapse, azacitidine

JOURNAL OPEN ACCESS

2020 Volume 59 Issue 21 Pages 2763-2767

DOI https://doi.org/10.2169/internalmedicine.4863-20

Browse “Advance online publication” version

Details

Abstract

We present the case of a 53-year-old woman with prefibrotic stage primary myelofibrosis (PMF) who underwent cord blood transplantation. Nine years after transplantation, she relapsed, which was confirmed by a bone marrow examination. We decided to treat her using azacitidine. After three courses of azacitidine, a partial cytogenetic response was confirmed. Azacitidine maintenance therapy successfully maintained a low level of recipient-origin peripheral blood cells with a stable hematological condition. Azacitidine may therefore be a promising therapeutic option for PMF patients who relapse after allogeneic stem cell transplantation.

Corresponding author

Register with J-STAGE for free!